Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% in ...

MitoRx Therapeutics (MitoRx), a platform biotechnology company developing novel mitochondrial-targeted sulfide-donor therapeutics (mtH2SD) in obesity-related disorders and myopathies announces the ...

A major population proteomics study using UK Biobank patient samples backed by 14 pharma companies has launched today with ...

Scientists have long considered ketones (a fundamental chemical class) and esters (molecules formed when an acid reacts with an alcohol) to be locked treasure chests of possibilities.

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Schwab U.S. Dividend Equity ETF is a clear buy with a look at its top 10 holdings. Click here to why I rate SCHD a Buy.

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...